AEs reported in at least 2 patients
| . | All cohorts (N = 18) . |
|---|---|
| Total patients with ≥1 AE, n (%) | 18 (100.0) |
| Total number of AEs | 150 |
| AEs reported in ≥2 patients, n (%) | |
| Nasopharyngitis | 8 (44.4) |
| Contusion | 7 (38.9) |
| Dental caries | 6 (33.3) |
| Pharyngitis | 5 (27.8) |
| Headache | 5 (27.8) |
| Excoriation | 4 (22.2) |
| Upper respiratory tract infection | 3 (16.7) |
| Tongue injury | 3 (16.7) |
| Wound | 3 (16.7) |
| Diarrhea | 3 (16.7) |
| Injection-site erythema | 3 (16.7) |
| Injection-site hematoma | 3 (16.7) |
| Injection-site pruritus | 3 (16.7) |
| Erythema | 3 (16.7) |
| Myalgia | 3 (16.7) |
| Infected dermal cyst | 2 (11.1) |
| Nausea | 2 (11.1) |
| Malaise | 2 (11.1) |
| Dizziness | 2 (11.1) |
| Back pain | 2 (11.1) |
| Rhinitis allergic | 2 (11.1) |
| Hemophilia | 2 (11.1)* |
| Calculus ureteric | 2 (11.1) |
| . | All cohorts (N = 18) . |
|---|---|
| Total patients with ≥1 AE, n (%) | 18 (100.0) |
| Total number of AEs | 150 |
| AEs reported in ≥2 patients, n (%) | |
| Nasopharyngitis | 8 (44.4) |
| Contusion | 7 (38.9) |
| Dental caries | 6 (33.3) |
| Pharyngitis | 5 (27.8) |
| Headache | 5 (27.8) |
| Excoriation | 4 (22.2) |
| Upper respiratory tract infection | 3 (16.7) |
| Tongue injury | 3 (16.7) |
| Wound | 3 (16.7) |
| Diarrhea | 3 (16.7) |
| Injection-site erythema | 3 (16.7) |
| Injection-site hematoma | 3 (16.7) |
| Injection-site pruritus | 3 (16.7) |
| Erythema | 3 (16.7) |
| Myalgia | 3 (16.7) |
| Infected dermal cyst | 2 (11.1) |
| Nausea | 2 (11.1) |
| Malaise | 2 (11.1) |
| Dizziness | 2 (11.1) |
| Back pain | 2 (11.1) |
| Rhinitis allergic | 2 (11.1) |
| Hemophilia | 2 (11.1)* |
| Calculus ureteric | 2 (11.1) |
All data collected after dose up-titrations were included.
Serious adverse event (SAE; left hip joint bleeding and subcutaneous hemorrhage of the proglossis).